Preclinical findings show that these compounds are highly selective towards mTOR as opposed to other kinases such as P13K, significantly inhibiting S6K and 4E-BP phosphorylation and inducing anti-tumour activity [262,265]. This evidence concerns the gene MTOR and neoplasm.